Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 14'th Nov 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic live
Delcath: Temporary Headwinds Are No Cause For Concern
02:15pm, Thursday, 06'th Nov 2025
Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which shou
Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript
05:16pm, Tuesday, 04'th Nov 2025
Delcath Systems, Inc. ( DCTH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - C
Delcath Systems, Inc. (DCTH) Q3 Earnings Match Estimates
10:16am, Tuesday, 04'th Nov 2025
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.03 per share a year ago.
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
08:00am, Tuesday, 04'th Nov 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic live
Analysts Set Delcath Systems, Inc. (NASDAQ:DCTH) Target Price at $24.00
03:19am, Friday, 31'st Oct 2025
Delcath Systems, Inc. (NASDAQ: DCTH - Get Free Report) has received an average recommendation of "Moderate Buy" from the five ratings firms that are presently covering the firm, Marketbeat Ratings rep
Delcath Systems to Host Third Quarter 2025 Earnings Call
08:30am, Tuesday, 21'st Oct 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it
Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript
05:05pm, Monday, 20'th Oct 2025
Delcath Systems, Inc. (NASDAQ:DCTH ) Discusses CHOPIN Trial Results and Preliminary Q3 Financials October 20, 2025 8:45 AM EDT Company Participants David Hoffman - General Counsel, Corporate Secretary
Delcath: Large Upside With Limited Downside Risk
03:06pm, Monday, 20'th Oct 2025
Delcath offers a liver-directed chemotherapy system, which is currently used to treat metastatic uveal melanoma patients. Delcath is facing pricing pressure and slow hospital onboarding at the moment,
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
04:15pm, Saturday, 18'th Oct 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
04:13pm, Saturday, 18'th Oct 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the result
Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
04:01pm, Monday, 22'nd Sep 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the accept
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 05'th Sep 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
08:30am, Tuesday, 19'th Aug 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the f
